Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy

Award Number: R43EY036695
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2025
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy - PROJECT SUMMARY Diabetic retinopathy (DR) is a major complication associated with Type 1 and Type 2 diabetes. Approximately 20% of patients with diabetes develop DR. DR is the leading cause of blindness in the working age population (20-74 years old) and affects more than 6.6 million adults in the U.S. alone. Existing therapies primarily target vascular hyperpermeability, which is responsible for intraocular pressure increase and visual disturbances. While antibodies against VEGF (ranibizumab, aflibercept), have shown clinical benefit and are now widely used for DR treatment, only 50% of patients with diabetic macular edema receiving anti-VEGF treatment have appreciable clinical benefit. This underscores the need for better treatments that address the upstream pathology and can provide treatment for both forms of DR including those refractory to anti-VEGF therapy. Current FDA-approved treatments do not address pathogenic mechanisms driving the disease. The pathophysiology of DR is related to prolonged exposure to high blood sugar, leading to non-specific glycation of proteins and subsequent formation of toxic advanced glycation end-products (AGEs). Evidence suggests that accumulation of AGEs play a role in the vascular and inflammatory complications associated with diabetes, including DR. Revel Pharmaceuticals has developed a novel class of therapeutics designed to cleave one of the most significant AGEs present in the eye, carboxymethyl-lysine (CML), thus removing a significant driver of DR. Our goal in this Phase I grant is to optimize lead drug candidates and demonstrate enzyme activity on physiologically relevant DR substrates. Our specific aims are to (1) engineer CML oxidase to efficiently cleave CML modifications from physiological substrates (2) characterize CML oxidase activity on human retinal tissue. Successful completion of this Phase I SBIR project will yield the first therapeutic enzyme designed to remove and repair AGE damage in vivo. In Phase II, we will carry out in vivo efficacy and IND-enabling studies with our collaborators at Vanderbilt Ophthalmic Contract Research Organization (VO-CRO) to support an IND submission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $358,065 )
2025	2025	REVEL PHARMACEUTICALS INC.	2325 3RD ST STE 214	SAN FRANCISCO	CA	94107	SAN FRANCISCO	USA	Vision Research	000	1	7/25/2025	NEW	$358,065
														Subtotal = $358,065

Grand Total All Awards = $358,065

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy

Award Number: R43EY036695

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2025

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer